

# Clinical Trial Protocol

## Iranian Registry of Clinical Trials

26 Jun 2026

### Comparison of vaginal misoprostol with and without vaginal estrogen in cervical ripening before operative hysteroscopy in postmenopausal women

#### Protocol summary

##### Study aim

Comparison of vaginal misoprostol with and without vaginal estrogen in cervical ripening before operative hysteroscopy in postmenopausal women referring to Rasool-e Akram hospital

##### Design

Clinical trial with control group, with parallel groups, single blinded, randomized, phase 3 on 102 patients.

##### Settings and conduct

This study was performed on 102 postmenopausal women who were candidate for hysteroscopy in Rasool-e Akram hospital. Patients were randomly divided into two groups e.i. patients in the intervention group were treated with one third of 4 gr applicator of vaginal cream 0.625 mg estrogen conjugate + misoprostol and control group receive only misoprostol. Patients and statistical analysts were blind.

##### Participants/Inclusion and exclusion criteria

Inclusion criteria were postmenopausal women (at least more than 1 year after the last menstrual cycle), candidates for hysteroscopy and patients must have a normal mammogram and Pap smear within the last 2 years. Exclusion criteria were recent or current pelvic infection, History of cervical conization, Previous surgery on the cervix, hypersensitivity to prostaglandins, History of venous thrombosis, Cardiovascular disease, Cervical or breast malignancies, Mullerian anomaly, Cervical anomalies

##### Intervention groups

Patients in the intervention group were treated with one third of 4 gr applicator of vaginal cream 0.625 mg estrogen conjugate + misoprostol. Control group receive only misoprostol.

##### Main outcome variables

Use of resectoscope, cervical softness, cervical stenosis, pain

#### General information

##### Reason for update

##### Acronym

##### IRCT registration information

IRCT registration number: **IRCT20211013052756N1**

Registration date: **2021-11-05, 1400/08/14**

Registration timing: **retrospective**

Last update: **2021-11-05, 1400/08/14**

Update count: **0**

##### Registration date

2021-11-05, 1400/08/14

##### Registrant information

##### Name

Mahsa Kiani

##### Name of organization / entity

##### Country

Iran (Islamic Republic of)

##### Phone

+98 21 2286 4111

##### Email address

dr.m.kiani87@gmail.com

##### Recruitment status

**Recruitment complete**

##### Funding source

##### Expected recruitment start date

2019-12-22, 1398/10/01

##### Expected recruitment end date

2021-02-18, 1399/11/30

##### Actual recruitment start date

2019-12-22, 1398/10/01

##### Actual recruitment end date

2021-01-19, 1399/10/30

##### Trial completion date

2021-04-21, 1400/02/01

## Scientific title

Comparison of vaginal misoprostol with and without vaginal estrogen in cervical ripening before operative hysteroscopy in postmenopausal women

## Public title

Comparison of vaginal estradiol in cervical ripening with misoprostol

## Purpose

Treatment

## Inclusion/Exclusion criteria

### Inclusion criteria:

Postmenopausal women (at least more than 1 year after the last menstrual cycle) Candidates for hysteroscopy Patients must have a normal mammogram and Pap smear within the last 2 years

### Exclusion criteria:

Recent or current pelvic infection History of cervical conization Previous surgery on the cervix hypersensitivity to prostaglandins History of venous thrombosis Cardiovascular disease Cervical or breast malignancies Mullerian anomaly Cervical anomalies

## Age

No age limit

## Gender

Female

## Phase

3

## Groups that have been masked

- Care provider

## Sample size

Target sample size: **102**

Actual sample size reached: **98**

## Randomization (investigator's opinion)

Randomized

## Randomization description

Restricted randomization with the permuted block method was used to create the random sequence and balance the number of allocated samples in intervention group (Vaginal misoprostol + estrogen, N=51) and control group (Vaginal misoprostol, N=51). The computer program was used for a random sequence using Excel, Rand function, in blocks of 2, 4, and 6. Each block has an equal number of control and HemoHIM groups. It is written on the cards and placed respectively for hiding in locked opaque packets. A packet was selected for each patient according to the study recruitment, which determines the related study group.

## Blinding (investigator's opinion)

Single blinded

## Blinding description

The patient is unaware of the allocation of drugs because he/she will be anesthetized and the statistical analyzer will receive the groups in the form of codes A and B and is unaware of the type of intervention in the groups.

## Placebo

Not used

## Assignment

Parallel

## Other design features

## Secondary Ids

empty

## Ethics committees

### 1

#### Ethics committee

##### Name of ethics committee

Ethics committee of Iran University of Medical Sciences

##### Street address

No8,amani street, shariati street, tehran,iran.

##### City

Tehran

##### Province

Tehran

##### Postal code

۱۹۴۸۶۴۳۴۵۱

#### Approval date

2019-11-26, 1398/09/05

#### Ethics committee reference number

IR.IUMS.FMD.REC.1398.374

## Health conditions studied

### 1

#### Description of health condition studied

Menopause

#### ICD-10 code

N95

#### ICD-10 code description

Menopausal and other perimenopausal disorders

## Primary outcomes

### 1

#### Description

Hegar cervical dilator during hysteroscopy

#### Timepoint

One during hysteroscopy

#### Method of measurement

Observation

## Secondary outcomes

### 1

#### Description

Cervical softness and stenosis

#### Timepoint

One during hysteroscopy

#### Method of measurement

Observation

### 2

#### Description

Pain

**Timepoint**

One 6 hours after hysteroscopy

**Method of measurement**

Visual analogue scale

**Intervention groups****1****Description**

Intervention group: Patients in the intervention group were treated with one third of 4 gr applicator of vaginal cream 0.625mg estrogen conjugate (each 1gr contains 0.625 mg conjugated estrogen produced by Aburaihan pharmaceutical Co) for 5 days the week before surgery as daily consumption at home. Also, this group received 200 micrograms of vaginal misoprostol tablets (Sami Saz Pharmaceutical Co) 6 hours before surgery.

**Category**

Treatment - Drugs

**2****Description**

Control group: This group received only 200 micrograms of vaginal misoprostol tablets (Sami Saz Pharmaceutical Co) 6 hours before surgery.

**Category**

Treatment - Drugs

**Recruitment centers****1****Recruitment center****Name of recruitment center**

Rasool-e-akram hospital

**Full name of responsible person**

Mahsa Kiani

**Street address**

No 8, Amani street , Shariati street. Tehran, Iran

**City**

Tehran

**Province**

Tehran

**Postal code**

۱۹۴۸۶۴۳۴۵۱

**Phone**

+98 21 2286 4111

**Email**

dr.m.kiani87@gmail.com

**Sponsors / Funding sources****1****Sponsor****Name of organization / entity**

Iran University of Medical Sciences

**Full name of responsible person**

Hossein Keyvani

**Street address**

Vice- Chancellor in Research Affairs of Iran University of Medical Sciences, Next to Milad tower, Hemmat highway, Tehran

**City**

Tehran

**Province**

Tehran

**Postal code**

۱۹۴۸۶۴۳۴۵۱

**Phone**

+98 21 2286 4111

**Email**

keyvani.h@iums.ac.ir

**Grant name****Grant code / Reference number****Is the source of funding the same sponsor organization/entity?**

Yes

**Title of funding source**

Iran University of Medical Sciences

**Proportion provided by this source**

100

**Public or private sector**

Public

**Domestic or foreign origin**

Domestic

**Category of foreign source of funding**

*empty*

**Country of origin****Type of organization providing the funding**

Academic

**Person responsible for general inquiries****Contact****Name of organization / entity**

Iran University of Medical Sciences

**Full name of responsible person**

Mahsa Kiani

**Position**

Resident

**Latest degree**

Medical doctor

**Other areas of specialty/work**

Gynecology and Obstetrics

**Street address**

No 8, Amani street, Shariati street , Tehran, Iran

**City**

Tehran

**Province**

Tehran

**Postal code**

1948643451

**Phone**

+98 21 2286 4111

**Email**

dr.m.kiani87@gmail.com

**Person responsible for scientific inquiries****Contact**

**Name of organization / entity**

Iran University of Medical Sciences

**Full name of responsible person**

Mahsa Kiani

**Position**

Resident

**Latest degree**

Medical doctor

**Other areas of specialty/work**

Gynecology and Obstetrics

**Street address**

No 8, Amani street, Shariati street, Tehran, Iran.

**City**

Tehran

**Province**

Tehran

**Postal code**

۱۹۴۸۶۴۳۴۵۱

**Phone**

+98 21 2286 4111

**Email**

dr.m.kiani87@gmail.com

**Person responsible for updating data****Contact****Name of organization / entity**

Iran University of Medical Sciences

**Full name of responsible person**

Mahsa Kiani

**Position**

Resident

**Latest degree**

Medical doctor

**Other areas of specialty/work**

Gynecology and Obstetrics

**Street address**

No8, Amani street, Shariati street , Tehran , Iran.

**City**

Tehran

**Province**

Tehran

**Postal code**

۱۹۴۸۶۴۳۴۵۱

**Phone**

+98 21 2286 4111

**Email**

dr.m.kiani87@gmail.com

**Sharing plan****Deidentified Individual Participant Data Set (IPD)**

No - There is not a plan to make this available

**Justification/reason for indecision/not sharing IPD**

There is no further information

**Study Protocol**

No - There is not a plan to make this available

**Statistical Analysis Plan**

No - There is not a plan to make this available

**Informed Consent Form**

No - There is not a plan to make this available

**Clinical Study Report**

No - There is not a plan to make this available

**Analytic Code**

No - There is not a plan to make this available

**Data Dictionary**

No - There is not a plan to make this available